Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 4, 2013, Pages 678-685

  Herman, Joseph M ^a   Fan, Katherine Y ^a   Wild, Aaron T ^a   Hacker Prietz, Amy ^a   Wood, Laura D ^a   Blackford, Amanda L ^a   Ellsworth, Susannah ^a   Zheng, Lei ^a   Le, Dung T ^a   De Jesus Acosta, Ana ^a   Hidalgo, Manuel ^b   Donehower, Ross C ^a   Schulick, Richard D ^c   Edil, Barish H ^c   Choti, Michael A ^a   Hruban, Ralph H ^a   Pawlik, Timothy M ^a   Cameron, John L ^a   Laheru, Daniel A ^a   Wolfgang, Christopher L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENCE INTERVAL; DUCTAL ADENOCARCINOMAS; INTENSITY-MODULATED RADIATION THERAPY; INTER QUARTILE RANGES; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; RADIATION THERAPY ONCOLOGY GROUPS; RECURRENCE-FREE SURVIVAL;

CHEMOTHERAPY; DISEASES; ENZYME INHIBITION; PHYSICAL THERAPY; RADIOTHERAPY;

CHEMORADIOTHERAPY;

CAPECITABINE; ERLOTINIB; GEMCITABINE;

ABDOMINAL PAIN; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; ENTERITIS; FAINTNESS; FATIGUE; FEMALE; FEVER; FISTULA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; INTENSITY MODULATED RADIATION THERAPY; INTESTINE ISCHEMIA; LYMPH NODE; MALE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RASH; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ERUPTIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; QUALITY OF LIFE; QUINAZOLINES; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84879210973     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.03.032     Document Type: Article

References (22)

1. A. Jemal, E.P. Simard, and J. Xu Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007 Cancer Causes Control 24 2013 559 565
2. T.P. Yeo, R.H. Hruban, and S.D. Leach Pancreatic cancer Curr Probl Cancer 26 2002 176 275
3. J.M. Herman, M.J. Swartz, and C.C. Hsu Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 26 2008 3503 3510
4. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial JAMA 297 2007 267 277
5. M.-L.H. Fjällskog, M.H. Lejonklou, and K.E. Oberg Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clin Cancer Res 9 2003 1469 1473
6. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
7. C. Bianco, G. Tortora, and R. Bianco Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 2002 3250 3258
8. W.W. Ma, J.M. Herman, and A. Jimeno A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer Transl Oncol 3 2010 373 379
9. P.Q. Bao, R.K. Ramanathan, and A. Krasinkas Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer Ann Surg Oncol 18 2011 1122 1129
10. C.H. Crane, G.R. Varadhachary, and J.S. Yordy Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression J Clin Oncol 29 2011 3037 3043
11. D.D. You, H.G. Lee, and J.S. Heo Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma J Gastrointest Surg 13 2009 1699 1706
12. K. Kato, S. Yamada, and H. Sugimoto Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: Influence of resection margin status on survival Pancreas 38 2009 605 612
13. M.M. Corsini, R.C. Miller, and M.G. Haddock Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005) J Clin Oncol 26 2008 3511 3516
14. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
15. B. Wacker, T. Nagrani, and J. Weinberg Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 2007 3913 3921
16. H. Haeno, M. Gonen, and M.B. David Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies Cell 148 2012 362 375
17. M.-S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer: Molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
18. S. Jones, X. Zhang, and D.W. Parsons Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
19. E. Massarelli, M. Varella-Garcia, and X. Tang KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896
20. E Ben Josef, M Schipper, and IR Francis A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 84 5 2012 1166 1171
21. B.G. Czito, C.G. Willett, and J.C. Bendell Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results J Clin Oncol 24 2006 656 662
22. W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial JAMA 299 2008 1019 1026